Hanall Biopharma Co (XKRX:009420) Net Income (Continuing Operations) : ₩-6,288 Mil (TTM As of Sep. 2024)

View and export this data going back to 1989. Start your Free Trial

What is Hanall Biopharma Co Net Income (Continuing Operations)?

Net Income (Continuing Operations) indicates the net income that a firm brings in from ongoing business activities. These activities are expected to continue into the next reporting period. Hanall Biopharma Co's Net Income (Continuing Operations) for the three months ended in Sep. 2024 was ₩222 Mil. Its Net Income (Continuing Operations) for the trailing twelve months (TTM) ended in Sep. 2024 was ₩-6,288 Mil.

Hanall Biopharma Co Net Income (Continuing Operations) Historical Data

The historical data trend for Hanall Biopharma Co's Net Income (Continuing Operations) can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Hanall Biopharma Co Net Income (Continuing Operations) Chart

Hanall Biopharma Co Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Net Income (Continuing Operations)

Get a 7-Day Free Trial

19,174.35

19,764.50

8,896.14

251.47

3,508.61

Hanall Biopharma Co Quarterly Data
	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24	Sep24
Net Income (Continuing Operations)	Get a 7-Day Free Trial															318.81	-2,863.12	-323.32	-3,323.56	221.93

Hanall Biopharma Co Net Income (Continuing Operations) Calculation

Net Income (Continuing Operations) indicates the net income that a firm brings in from ongoing business activities. These activities are expected to continue into the next reporting period.

Net Income (Continuing Operations) for the trailing twelve months (TTM) ended in Sep. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was ₩-6,288 Mil.

Hanall Biopharma Co (XKRX:009420) Net Income (Continuing Operations) Explanation

Net Income (Continuing Operations) excludes extraordinary items, income from the cumulative effects of accounting changes, non-recurring items, income from tax loss carry forward, and preferred dividends.

Hanall Biopharma Co Net Income (Continuing Operations) Related Terms

Thank you for viewing the detailed overview of Hanall Biopharma Co's Net Income (Continuing Operations) provided by GuruFocus.com. Please click on the following links to see related term pages.

Hanall Biopharma Co Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Hanall Biopharma Co Ltd (XKRX:009420) » Definitions » Net Income (Continuing Operations)

Traded in Other Exchanges

N/A

Address

12 Bongeunsa-ro 114-gil, Daewoong Building, 3rd Floor, Gangnam-gu, Seoul, KOR

Website

http://www.hanall.co.kr

Hanall Biopharma Co Ltd is a part of the healthcare sector. It is one of Korea's leading pharmaceutical companies and is focused on drug delivery, biotherapeutics, and new small molecule discovery. The company's scope comprises of ophthalmology, immunology, cardiovascular treatment and dermatology.

Hanall Biopharma Co Headlines

No Headlines